Skip to main content
Industry Insights

Industry Insights · Brain–Computer Interface

BCI industrialization accelerates: from 'concept race' to 'execution'

BCI momentum is turning from a capital narrative into verifiable clinical and industrial progress.

Published:2026-06-07Updated:2026-06-07

Updated
Illustration of key BCI industrialization milestones
Key BCI industrialization milestones: high-throughput implant trials, a jump in quarterly funding, and a policy mention. Illustrative.
In short: China's first 128-channel fully implantable BCI system entered multi-center trials, marking high-throughput invasive tech moving from lab to clinic. Capital and policy warmed in step: Q1 2026 saw 17 BCI deals worth ~RMB 3.8B, beating all of 2025; BCI entered the government work report as a priority future industry. The logic has shifted from 'hype and land-grab' to 'execution and industrialization capability'.

Clinic enters the high-throughput stage

Channel count is a key metric for invasive BCI. China's first 128-channel fully implantable system entering multi-center trials raises the bar on acquisition scale and integration — and on electrodes, chips and encapsulation.

Capital and policy resonance

Q1's 17 deals and ~RMB 3.8B exceeded all of 2025; BCI entered the government work report as a future industry. Money and policy favor teams with clear clinical paths and manufacturing capacity.

The competitive focus moves

As the field shifts from 'newest concept' to 'who can ship', engineering across electrode–chip–encapsulation–system, plus materials and manufacturing stability, becomes the divide.

The BIO angle

Higher channel counts demand more of electrode insulation, dense-lead encapsulation and long-term reliability. Medical silicone and polymer encapsulation grow more central in high-throughput implants — a direction BIO tracks closely.

FAQ

Why does 128-channel matter?

More channels means more neural sites read/stimulated at once and richer information — but it raises demands on electrode density, lead encapsulation and integration.

What does RMB 3.8B in a quarter signal?

Capital is moving from proof-of-concept toward teams with clinical and industrial paths; the field has entered an 'execution' phase.

Is this investment advice?

No. This is an industry overview only, with no stock or investment recommendation.

Related reading

Browse all insights →

Note: an original analysis compiled from public industry information; figures and conclusions per official/original sources. Not investment advice.

Building in China's medical-device market?

From advanced medical silicone/polymers to material selection, regulatory and supply, BIO helps global and local partners move from selection to landed supply in China.